Clone generation from either hybridoma, phage display or from B cell generates thousands of potential leads. Screening for a primary selection of optimal leads is usually done with an ELISA based Protein-Protein Interaction (PPI).
The hits or compounds with the strongest affinity to the target of interest are picked and follow-up screening is performed in various functional assays to determine the biologic candidate’s therapeutic potential.
We offer multiple chemistries for high throughput antigen-protein elucidation which accoupled with our integrated automation solutions can save your time and move you quickly toward your lead discovery workflows.
With dedicated workstations designed for a diverse variety of applications, along with the ability to customize liquid handling workstations based on your needs, 爱游戏平台注册登录 's innovative automated liquid handling solutions enable you to minimize errors, reduce hands-on time, and increase throughput and reproducibility.
Your job is to move from target to hit to candidate quickly and efficiently – with as little wasted resources as possible. Our drug discovery screening reagents do just that.
Whether you are doing high throughput screening or focused screening, we offer a wide range of validated reagents and kits in Alpha chemiluminescent, LANCE® TR-FRET, DELFIA® TRF, and other assay technologies to suit you screening assay needs.
Modulation of protein interactions can affect signal transduction, growth factor, gene expression, and other factors, making it a promising new avenue for protein-base treatments. Development of protein-based therapeutics requires a thorough understanding of protein function and interactions.
Our protein-protein interaction assays and instruments allow fast, multimode detection of protein-protein interactions for drug discovery.
The full measurement capabilities of our protein-protein interaction analysis technologies include:
